UBS analyst David Lai raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $88 and keeps a Neutral rating on the shares after Sanofi (SNY) announced its intention to acquire Blueprint for up to $9.5B including a contingent value right.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley
- Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties
- Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Blueprint Medicines upgraded to Neutral from Sell at Citi
- Blueprint Medicines downgraded to Neutral from Buy at Guggenheim